Hernández-Valencia M

Language: Spanish
References: 24
Page: 419-423
PDF size: 124.60 Kb.

ABSTRACT

The female population in conditions of greater demand of insulin production, as in the case of pregnancy, can develop gestational diabetes (DG); therefore, the preconceptional attention in patients with suspects of development of DG should include the confirmation that blood glu-cose is found within the normal range, as well as the indication of a controlled diet. Glucose posprandial determinations two hours after food intake is advisable in patients that need insulin administration, which avoids determinations four times a day. The diet should include between 35 and 40 % of carbohydrates per day, super-vised by a dietitian and based on the needs of each woman and the characteristics of the gestation. The combination of ultra-rapid acting insulin associate to ultra-slow acting insulin for application as a unique dose per day has been successfully used, but it is still necessary to determine the best diet for an adequate control of glucose. Oral hypoglycemic medications are not recommended as a DG treatment, since they were traditionally described as having theratogenic activity, by maintaining long hypoglycemic periods. Vaginal delivery is not contraindicated, although to avoid obstetrical complications, a cesarean section can be practiced, taking into account the antecedents of prior birth weight and the characteristics of bone pelvis. After delivery, a monthly posprandial determination at 2 hours should be carried out, where concentrations under 140 mg/dL are considered normal and it should be repeated every year. Insulin resistance can be a physiological state of pregnancy, but the beta-cells of maternal pancreas can be altered from the fetal life and therefore, cause the impossibility to respond to such a metabolic effort as pregnancy.

REFERENCES

1. Casele HL, Laifer SA. Factors influencing preconception control of glicemia in diabetic women. Arch Intern Med 1988;158:1321-1324.

2. Hernández-Valencia M, Carrillo PA. Control prenatal asociado al número de consultas como método diagnóstico de hiperglucemia. Ginecol Obstet Mex 2002;70:592-596.

3. Kjos SL, Peter RK, Xiang A, Henry OA, Montoro M, Buchanan TA. Predicting future diabetes in Latino women with gestational diabetes: utility of early postpartum glucose tolerance testing. Diabetes 1995; 44:586-591.

4. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care 2002;25:1862-1868.

5. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:214-223.

6. Zárate A, Hernández-Valencia M, Tene CE. Impacto clínico de la resistencia a la insulina y la relación con la prevención de diabetes mellitus. Gac Med Mex 1998;134:647-649.

7. Friedman JE, Ishizuka T, Shao J, Huston L, Highman T, Catalno P. Impaired glucosa transport and insulin receptor tyrosine phosphorylation in skeletal muscle from obese women with gestational diabetes. Diabetes 1999;48:1807-1814.

8. Winzer C, Wagner O, Festa A, Schneider B, Roden M, Bancher-Todesca D, Pacini G, Funahashi T, Kautzky-Willer A. Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior ges-tational diabetes mellitus. Diabetes Care 2004;27: 1721-1727.

9. Shao J, Catalano PM, Yamashita H. Decreased insulin receptor tyrosine kinase activity and plasma cell membrane glycopreotein-1 overexpression in skeletal muscle from obese women with gestational diabetes mellitus. Diabetes 2000;49:603-610.

10. American Diabetes Association: Gestational diabetes mellitus (position statement). Diabetes Care 20004; 27(S1):88-90.

11. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982;144:768-773.

12. Dornhorst A, Girling J. Management of gestational diabetes mellitus. New Engl J Med 1995;333:1281-1283.

13. Avery MD, Leon AS, Kopher RA. Effects of a partially home-based exercise program for women with gestational diabetes. Obstet Gynecol 1997;89:10-15.

14. Coustan DR, Lewis SB. Insulin therapy for gestational diabetes. Obstet Gynecol 1978;51:306-310.

15. Thompson DJ, Porter KB, Gunnells DJ, Wagner PC, Spinnato JA. Prophylactic insulin in the management of gestational diabetes. Obstet Gynecol 1990;75:960-964.

16. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356:443-445.

17. Kudva YC, Basu A, Jenkins GD, Pons GM, Quandt LL, Gebel JA, Vogelsang DA, Smith SA, Rizza RA, Isley WL. Randomized controlled clinical trial of glargine versus ultralente insulin in the treatment of type 1 diabetes. Diabetes Care 2005;28:10-14.

18. Jovanovic L, Illic S, Pettitt DJ, Hugo K, Gutiérrez M, Bowsher RR. The effect of tolbutamide on rat embryonic development in vitro. Teratology 1993; 48:48:45-51.

19. Zárate A, Ochoa R, Hernández-Valencia M, Basurto L. Eficacia de la Acarbosa para controlar el deterioro de la tolerancia a la glucosa durante la gestación. Ginecol Obstet Mex 2000;68:42-45

20. Zárate A, Hernández-Valencia M, Fonseca ME, Ochoa R. Empleo de metformin en el manejo de adolescentes con el síndrome de ovarios poliquísticos. Ginecol Obstet Mex 1997;65:504-507.

21. Rouse DJ, Owen J, Goldenberg RL, Cliver SP. The effectiveness and costs of elective cesarean delivery for fetal macrosomia diagnosed by ultrasound. JAMA 1996;276:1480-1486.

22. Hernandez-Valencia M, Carrillo PA. Glucose screening during active labour for the detection of undiagnosed hyperglycaemia and newborn malformations in a population without pre-natal care. Diabetes Obesity Metabolism 2002;4:1-6.

23. Xiong X, Saunders LD, Wang FL, Demianczuk NN. Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes. Int J Gynaecol Obstet 2001;75:221-228.

24. Silverman BL, Rizzo TA, Cho NH, Metzger BE. Long-term effects of the intrauterine environment. Diabetes Care 1998;21:142-149.